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Prolongation of greater occipital neural blockade 
with 10% lidocaine neurolysis: a case series of a 
new technique
David Daewhan Kim
nabil sibai
Department of anesthesiology/
Pain Medicine Division, henry Ford 
hospital, Detroit, Mi, Usa
Introduction: Greater occipital nerve blocks (GONB) have been used for headache but their 
benefit may be short. Ready et al performed intrathecal injections  on rabbits and reported 
neurologic/histologic changes that required concentrations of at least 8%. Our study tests the 
hypothesis that the neurolytic effects of GONB with 10% lidocaine can prolong relief.
Methods: After an approval from Henry Ford Hospital Institutional Review Board, a chart review 
was performed for patients who had GONB with 10% lidocaine. Patients received 10% lidocaine 
after short response (<1 month / >50% relief) to GONB with 1 cc of a solution containing 9 mL 
0.5 % bupivacaine and 40 mg methylprednisolone. They received a block with 10% lidocaine 
with volume given at <80% of the maximum dose of 4 mg/kg. Injections were performed under 
fluoroscopic guidance after injection of 0.1 cc of contrast (isovue or magnevist). All patients had 
intravenous access and were given fentanyl and midazolam. The visual analog scale (VAS) scores 
were recorded on follow-up, and the duration of response was noted. VAS changes with 10% 
lidocaine and comparison of duration with methylprednisolone were performed using paired t-test.
Results: Thirteen patients were reviewed; 12 were female and the mean age was 47. Ten were 
diagnosed with migraine, and three with occipital neuralgia; 12 had bilateral symptoms. Base-
line VAS prior to 10% lidocaine averaged 86.92 mm. The mean volume injected per nerve was 
1.096 mL. There was significant decrease in mean% VAS with 10% lidocaine at 60.4% (mean: 
−52.69 mm) (P=0.001). The mean duration of relief was significantly higher with 10% lidocaine 
at 148.05 days ([standard deviation]=98.87) versus methylprednisolone at 6.33 days (standard 
deviation=5.01) (P=0.001). No complications or side effects were reported.
Conclusion: Ten percent lidocaine may be a useful neurolytic agent in prolonging the dura-
tion of GONB.
Keywords: pain relief, migraines, occipital neuralgia, intractable headaches, injections
Introduction
Chronic migraine and occipital neuralgia are common causes of intractable headache 
with prevalence of (1.4%–2.2%) for migraine and (0.4%–4%) for occipital neuralgia.1,2 
Medication management has traditionally been limited in efficacy, tolerability, and 
compliance.3 Greater occipital nerve blocks (GONB) have been used to treat various 
headache syndromes such as migraine, greater occipital nerve (GON), cluster head-
ache, cervicogenic headache, and even dural puncture headache that are refractory 
to other treatments.3–7 The mechanism of action has been speculated to be due to the 
convergence of sensory afferents from C2 and the trigeminal nerve.8,9 The duration 
of pain relief obtained from GONB has been shown to be quite variable and short 
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in duration. Lambru et al in a prospective open-label study 
of cluster headache patients reported a mean duration of 
21 days.6 Siddiqui and Caplinger evaluated the efficacy of 
occipital nerve blocks for chronic migraine with and without 
bupivacaine, and reported mean duration of either 23.7 and 
22.6 days, respectively, with a range of 1–90 days.10 Afridi et 
al performed GONB for various primary headache syndromes 
and reported a mean duration of partial response of 61 days.11 
Due to the short duration of relief with GONB, radiofre-
quency ablation (RFA) using pulsed, cooled, and continuous 
ablation has been used to prolong relief.12–16 However, these 
are not without complications, especially with continuous 
RFA, which can cause post-denervation neuralgia.12–16 Due 
to the current fiscal environment in the US, alternatives such 
as cooled and pulsed RFA may not be reimbursed by insur-
ance. The use of chemical neurolysis with phenol and alcohol 
in the thin tissue of the GON may be problematic given the 
risk of anesthesia dolorosa and necrosis of surrounding soft 
tissue.17–19 Lidocaine has been demonstrated to be neurotoxic 
in multiple animal and cell culture studies.20–34 Ready et al in 
1985 performed intrathecal injections of 2%–32% lidocaine 
on rabbits and followed neurologic function for 7 days prior 
to harvesting the spinal cords for histology.24 They reported 
persistent neurologic deficit and major histologic changes 
starting at 8% concentration. The reports of clinical use of 
higher concentration lidocaine for chronic pain were highly 
limited. Choi and Liu reported three cases of patients who had 
months of relief with peripheral nerve blocks of 5% lidocaine 
with 7.5 dextrose.35 Only one of the cases was a GONB for 
post-herpetic neuralgia, which lasted 8 months. Their study 
was problematic given the small number and the concen-
tration used by Choi was less than the 8% concentration 
threshold for neurolysis seen in animal study by Ready et al. 
Also Hempl et al demonstrated that the addition of dextrose 
and lower concentration lidocaine did not show consistent 
neurolytic symptoms in the context of increased transient 
neurologic symptoms (TNS) in spinal anesthesia.36 Kim et 
al demonstrated that 10% lidocaine caused rapid neurolytic 
changes in the sciatic nerve in a canine.37 Therefore, this 
study tests the hypothesis that lidocaine >8% concentration 
can be an alternative neurolytic agent in the prolongation of 
headache relief with GONB in a retrospective chart review.
Methods
After Institutional Review Board at Henry Ford Hospital 
(Detroit MI) approval, a retrospective chart review was 
performed on all patients who received GONB with 10% 
preservative-free lidocaine for headache from January 2014 
to June 2015  after referral for occipital nerve block from 
neurology service. Ten percent preservative-free lidocaine was 
compounded by Health Dimensions Compounding Pharmacy 
(Farmington, MI, USA). Those patients who received 10% lido-
caine had to have ≥50% relief on visual analog scale (VAS) for 
<1 month with GONB using bupivacaine/methylprednisolone 
(BM). Demographic information including age, sex, laterality, 
diagnosis, and baseline VAS prior to 10% lidocaine GONB was 
recorded. As per routine in our clinic, patients were asked to 
follow-up once they felt the headaches had return to baseline. 
On follow-up, the VAS during the period of relief and duration 
of relief as reported by patients was recorded. Duration of relief 
with initial GONB with BM was noted. All GONB were per-
formed by the same provider. GONB with BM were performed 
at the bedside. After written informed consent was obtained 
for the whole study as per standard practice of care, GONB 
with 10% lidocaine was performed with the patients in prone 
position in a cervical headrest under fluoroscopic guidance to 
exclude vascular uptake with sedation of intravenous fentanyl 
and midazolam. The volume of 10% lidocaine used was up to 
80% max dose of lidocaine based on 4 mg/kg body weight, 
and 0.1 cc isovue or magnevist contrast was injected prior to 
exclude vascular uptake to reduce the risk of lidocaine toxic-
ity. Of note, patients who received bilateral GONB received a 
smaller dose/volume of 10% lidocaine due to the dose limit of 
4 mg/kg. Statistical analysis was performed using paired t-test.
Results
A total of 13 patients were reviewed. All but one patient was 
female, and the average age was 47 years (standard deviation 
[SD]=15.42) (Table 1). Ten were diagnosed with migraine 
and three with  occipital neuralgia. Eleven had bilateral 
symptoms (Table 1). Baseline VAS prior to GONB with 10% 
lidocaine averaged 86.92 mm (SD=11.82) (Table 2). The 
mean volume of 10% lidocaine injected per nerve was 1.096 
mL (SD=0.38) (Table 1). There was significant decrease in 
mean % change VAS with 10% lidocaine at 60.4% (mean: 
−52.69 mm) (P=0.001) (Table 2). The mean duration of relief 
was significantly higher with 10% lidocaine at 148.05 days 
(SD=98.87) versus BM at 6.33 days (SD=5.01) (P=0.001) 
(Table 3). No complications or side effects were reported.
Discussion
Relationship of concentration of lidocaine 
and neurolysis
Most animal studies have used concentrations of 5% or 
less to study neurotoxicity since this is the most common 
concentration used clinically. Previous studies used direct 
intraneural or intrathecal injections, desheathed nerves, and 
cell cultures. Only one paper by Kalichman et al mentions 
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lidocaine being injected perineurally by piercing the con-
nective tissue separating the neural tissue from overlying 
muscle rat sciatic nerves.22 They measured nerve conduction 
post-injection and performed histologic analysis at 48 hours. 
They reported endoneurial edema, collapsed myelin sheaths, 
and axonal degeneration. This study, however, used a lower 
concentration than seen in previous studies at 3% lidocaine. 
Although animal models have shown evidence of neurotoxic-
ity at clinically used concentrations of 5% or less, evidence of 
neurotoxicity in humans at these concentrations appeared to 
be much less than expected. This has been well documented 
in the use of intrathecal lidocaine for spinal anesthesia and the 
phenomenon of TNS. Schneider et al reported four cases of 
TNS using 5% lidocaine.34 Keld et al compared 5% lidocaine 
versus 0.5% bupivacaine  and found that lidocaine caused 
TNS in 26% of patients versus 3% in bupivacaine.38 Several 
prospective studies noted TNS incidence of 4%–33% with 
lidocaine.30,31 This may be explained by the study of Ready 
Table 1 Patient demographics and dose of 10% lidocaine used
Diagnosis Male=1 Female=1 Age Bilateral=1 Dose (mL) per site 
10% lidocaine
Migraine 0 1 19 0 1.5
Migraine 0 1 38 1 1
Migraine 0 1 45 1 1
Migraine 0 1 67 1 1
Migraine 0 1 48 1 1
Migraine 0 1 52 1 1
Migraine 0 1 65 1 1
Occipital 0 1 69 1 0.75
Migraine 0 1 57 1 1
Migraine 1 0 36 1 1.5
Occipital 0 1 35 0 2
Migraine 0 1 28 1 1
Occipital 0 1 52 1 0.5
Migraine (n=10) Occipital (n=3) Male=1 12 Mean=47 Bilateral=11 Mean=1.096154
Table 2 Vas baseline and post 10% lidocaine
Diagnosis Base VAS before  
10% lidocaine (mm)
Post-VAS after  
10% lidocaine (mm)
Change VAS (mm) % change VAS
Migraine 80 20 60 75
Migraine 90 22.5 67.5 75
Migraine 100 62.5 38.5 38.5
Migraine 100 60 40 40
Migraine 70 40 30 40.4
Migraine 90 50 40 44.4
Migraine 70 30 40 57.14
Occipital 80 30 50 62.5
Migraine 90 22.5 67.5 75
Migraine 90 22.5 67.5 75
Occipital 100 25 75 75
Migraine 70 30 40 57.2
Occipital 100 30 70 70
Mean 86.9230769 34.2307692 50.25 60.39538462 (P=0.0001)
sD 11.82 14.48 15.56 15.10
Abbreviations: sD, standard deviation; Vas, visual analog scale.
Table 3 comparison duration of maintenance of pain relief of 
bupivacaine/methylprednisolone test block with 10% lidocaine
Diagnosis Duration  
from test  
block (days)
Duration  
from 10% 
lidocaine (days)
Change in 
duration (days)
Migraine 14 210 +196
Migraine 0.333 365 +364.667
Migraine 2 220 +218
Migraine 1 71 +70
Migraine 7 24 +17
Migraine 14 287 +273
Migraine 4 60 +56
Occipital 7 123 +116
Migraine 7 120 +113
Migraine 7 90 +83
Occipital 4 221 +217
Migraine 1 96 +95
Occipital 14 120 +106
Mean 6.333307692 154.3846154 +149.05
sD 5.01 98.87 (P-value=0.0001)
Abbreviation: sD, standard deviation.
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et al who reported prolonged neurologic deficit and profound 
histological changes after intrathecal injection in rabbits 
occurred only at lidocaine concentrations ≥8%, which was 
compatible with the previously mentioned clinical experi-
ence in humans. In our study, 10% lidocaine allowed local 
concentrations ≥8% despite the requirement to inject contrast 
beforehand to exclude vascular uptake.
extraneural local toxicity of lidocaine
Our study did not find gross acute changes to the surround-
ing soft tissue after injection. Phenol and alcohol have been 
well known to cause significant necrosis in tissue other than 
neural tissue. Besides the obvious cardiac and central nervous 
system toxicity with lidocaine, which was controlled in our 
study by dose and image guidance, review of literature does 
not indicate significant soft tissue injury with lidocaine. 
Only two case reports or series have been published in the 
ophthalmology literature with cases of ptosis and diplopia 
after lidocaine injection for retro-orbital nerve blocks caus-
ing what is presumed to be due to ocular muscle necrosis 
but not proven by biopsy.32,33 Sahai-Srivastava and Subhani 
reviewed the side effects of different concentrations of 
lidocaine in their retrospective analysis of 89 patients who 
received GONB with 1% (N=69), 2% (N=18), and GONB 
with 5% lidocaine.39 They reported adverse effects such 
as dizziness, hypertension, blurry vision, slurred speech, 
and pseudo-seizure in 9% of patients with four patients in 
the 5% group and three in the 1% group. They reported no 
statistically significant correlation between lidocaine dose 
and occurrence of adverse effects, though there was a slight 
trend toward more adverse effects in the lidocaine 5% group 
(P=0.072) compared to the lidocaine 1% group. Their study 
was limited since it did not mention the total mg of lidocaine 
used or volume. In our study, the risk of inadvertent vascular 
was decreased by using contrast and fluoroscopy. The total 
dose of lidocaine was kept below the recommended dosage 
limits, and the patients received midazolam and fentanyl 
to raise seizure threshold and decrease anxiety, which may 
contribute to the hypertension seen in the previous study.
comparison of lidocaine to RFa
Gabrhelík et al in a pilot study compared the efficacy of 
pulsed RFA of the greater occipital nerve versus GONB with 
a mixture of local anesthetic and steroid in the management 
of refractory cervicogenic headache.12 They reported that pain 
remained reduced even after 9 months. Navani et al described 
a case of pulsed RFA of the GON obtaining 4 months’ pain 
relief.13 Hamer and Purath performed continuous RFA of the 
C2 dorsal root ganglion with or without third occipital nerve 
in an observational study of 40 patients with cervicogenic 
headache and occipital neuralgia.16 They reported a mean 
duration of pain relief at 22.35 weeks; however, 12.5% of 
the study patients reported hyperesthesia along the GON and 
lesser occipital nerve on the side treated. This lasted between 
1 and 6 months at the time of follow-up. The use of cooled 
RFA was limited to a single case report and only the acute 
response was measured.15 The duration of GONB with 10% 
lidocaine at 148 days appeared to be at least comparable in 
duration to pulsed RFA and continuous RFA without the 
side effects. No dysesthesia was reported by any of the 10% 
lidocaine GONB patients.
Conclusion
In this case series, 10% lidocaine does appear to prolong 
the relief of headache and may have neurolytic action with-
out side effects. The study was limited by its retrospective 
nature, small number of patients, and nonstandardized time 
for follow-up requiring self-report by patients. Given that, 
further investigation with a randomized controlled trial is 
warranted to confirm results. Also, further studies are needed 
to see if 10% lidocaine is a viable alternative to RFA of the 
occipital nerve in the treatment of headache.
Disclosure
The authors report no conflicts of interest in this work.
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